Investors don’t want to make the bet because it’s too hard to call.

Recent results provide clear evidence of the turnaround at Schering-Plough and the positive momentum of the cholesterol joint venture.

You want to educate people on the condition and how to avoid it.

Expectations are fairly low, and these companies will deliver results that are in-line, or slightly better than expectations.

This is as good as it gets for Pfizer. They won a victory on both patents — well beyond our expectations.

A lot of their big drugs are going to lose patent protection, without the introduction of new drugs that will offset that, … buy.